Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Portugal

Coordination and Support Action · Running

NIMSB NOVA Institute for Medical Systems Biology

Coordinator
Nova Imsb Nova Institute for Medical Systems Biology Associacao, Portugal
Runs
1 September 2023 to 31 August 2029
Status
Running
EU funding
€15.0m
Total cost
€15.0m
Partners
3 organisations in 2 countries
Type
Coordination and Support Action
Grant agreement
101060346

What the project is doing

In the project's own words, from its summary on CORDIS.

The rise of chronic diseases is shaping health policy priorities worldwide. As the population ages, these conditions affect increasing portions of society and are more difficult to manage, causing suffering in patients and their families for many years. Such increasing prevalence is a threat to the sustainability of healthcare systems. Thus, an increasing focus has been put on disease prevention and awareness, as well as on precision medicine.

The Teaming project will create a new Centre of Excellence, NOVA Institute for Medical Systems Biology (NIMSB), which will use the most advanced cell analytics and experimental in vitro systems, combined with computational approaches to understand and fight chronic diseases. The core of the project will be the integration of multi-omics data from single cells from patient biopsies and derived organoids, bioinformatics and artificial intelligence, cell and molecular biology, and relevant animal model studies, to develop quantitative models that can inform on mechanisms of disease progression.

Researchers and clinicians will collaborate to use this knowledge to implement novel precision medicine solutions, aiming to intercept diseases before symptoms develop, and also by improving diagnosis, disease course prediction and response to treatment. NIMSB will contribute to clinical practice improvement not only with technology but also by training the next generation of researchers and medical doctors in precision interceptive medicine and digital-transformation technologies.

The Max Delbrück Center for Molecular Medicine is the best possible advanced partner, as it is a world leader in this research topic and has recently created the Berlin Institute for Medical Systems Biology, which is a model for NIMSB. Champalimaud Foundation (FC) (PIC 967498371, VAT: 507131827) is included as a third-party entity providing in-kind contributions, in accordance with Article 9.2 of the Horizon Europe Model Grant Agreement.

The FC costs will be reported with no profit margin, under internal rates applied to FC researchers, and will be supported by complementary (non-HEU) funding sources.

Topics

Who is involved

OrganisationCityCountryRole
Nova Imsb Nova Institute for Medical Systems Biology AssociacaoPaco De ArcosPortugalCoordinator
Max Delbrueck Centrum Fuer Molekulare Medizin in Der Helmholtz-Gemeinschaft (mdc)BerlinGermanyParticipant
Universidade Nova De LisboaLisboaPortugalParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI